• Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
• He received Cyclotron Trust Award with travel grant to attend the Education Sessions of PTCOG-58 conference held in Manchester, United Kingdom between 10-15June,2019.
• He was selected for ESMO preceptorship on Head & neck cancer which was held in  Zurich, Switzerland between,May,2019
• Having qualified for the award of Diplomate of the National Board of Examinations in Radiotherapy at the examination held in December, 2013; He has been  admitted by the council as member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018

• International training fellowship in St James University Hospital (Leeds teaching hospital), UK from March 2017- October 2018.
• Fellowship in Clinical oncology from Tata Medical Center, Kolkata, India from June, 2013 to January, 2017.
• He was selected for ESMO preceptorship on Brain tumor held between September 28, 2018-September 29, 2018 in Athens, Greece.
• FRCR in Clinical Oncology awarded by Royal College of Radiologists in April,2018
• Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in controversies in Clinical Oncology, which was held in Kolkata, India in 2016.
• He had an oral presentation in The Royal College of Radiologists proffered paper session in NCRI conference 2015, Liverpool, UK; for which He got ‘The Company of Biologists Travel Award’
• ‘Is daily MVCT imaging really required in helical tomotherapy for head and neck cancers? : An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata,India.

Dr Saha has participated as a sub investigator in many international trials. Some of the trials are-

• A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
• Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (ABC07 trial)
• A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE trial)
• ETOP/IFCT 4-12 STIMULI trial which is an Open-label, randomised, two-arm, phase II trial looking into addition of Immunotherapy with Nivolumab and Ipilumumab to standard of care  in limited stage Small cell lung carcinoma.
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
• GO40241 Phase III randomized, double-blind, placebo-controlled study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
• Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer: A randomised phase III trial (SARON study)
• A multi-centre randomised study of induction chemotherapy followed by capecitabine(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP 2 study)
• A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma. (SYSTEM 2 trial).
• A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
• A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006).
• Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study).
• Adjuvant Durvalumab following sequential chemotherapy and radiotherapy in patients with unresecatble stage III NSCLC (PACIFIC 6 study).

Dr Saha has numerous publications in national and international peer reviewed journals. Some of his publications include-

• Can Dosimetry Affect Overall Survival in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)? An Analysis of 1300 Patients. 
• Setting up a lung Stereotactic Body Radiotherapy (SBRT) service in a tertiary centre in eastern India– The process, quality assurance and early experience. 
• Radical radiotherapy or chemoradiotherapy for inoperable locally advanced non-small-cell lung cancer (NSCLC) - Analysis of patient profile, treatment approaches and outcomes of 213 patients at a tertiary cancer centre. 
• A Prospective Study of an Offline Matching Protocol for Head and Neck Cancer on Helical Tomotherapy: The F5 Study.
• Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study. 
• High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
• Quality Assurance and Acute Toxicities of a 2 Week Hypofractionated Palliative Radiotherapy Schedule used in a Prospective Phase I/II Study (HYPORT Study).
•  Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of Large Number of Daily Imaging-based Corrections. Clin Oncol, 2016.
• Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators? 
• Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer.
•  A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.